Opinion|Videos|June 11, 2024
Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening
Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.
Advertisement
Episodes in this series
Advertisement
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Elevated PSA in Primary Care: What to Consider Before Biopsy
3
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
4
FDA Clears Beta Bionics’ Mint Reusable Insulin Patch Pump
5